AbbVie (ABBV) delivered
exceeded estimates in Q4 and financial year 2024 as displayed by numerous reports spanning earnings call transcripts, sales results, revenue beats, and stock growth. Despite Humira’s decline, new drug sales supplemented the gap well.
Strong revenue growth and strategic planning formed a part of Q4 highlights, with AbbVie stock rising notably. Partnership with Neomorph for Molecular Glue Degraders, acquisition of Nimble Therapeutics to fortify immunology pipeline, along with updates on the ABBV-RGX-314 Clinical Program and positive results from Phase 3 TEMPO-1 Trial for Parkinson's disease highlighted innovation in both oncology and immunology. AbbVie’s upward journey witnessed several investment entities amplifying their stock holdings. However, Q4 also noted a minor earnings fall despite a 6% revenue growth. Looking ahead,
ABBV issued FY 2025 earnings guidance suggesting a positive outlook. News of Independence Bank of Kentucky, Concord Wealth Partners, Caprock Group, and various others increasing their stake in AbbVie further boosted its stock value.
Abbvie ABBV News Analytics from Thu, 26 Sep 2024 07:00:00 GMT to Sat, 01 Feb 2025 14:30:51 GMT -
Rating 9
- Innovation 5
- Information 7
- Rumor -4
